ISM6331

Phase 1Small molecule

IInSilico Medicine Hong Kong Limited

ISM6331 is one of 52 small molecule programs targeting Malignant Mesothelioma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Malignant MesotheliomaActive, not recruiting

Malignant MesotheliomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

65 competitors in Malignant Mesothelioma

#DrugCompanyPhaseTrials

Imjudo

AstraZeneca

Phase 3

3 2

Opdivo

Bristol-Myers Squibb

Phase 2

2 3

Lynparza

AstraZeneca

Phase 2

2 4

Nexavar

Bayer

Phase 2

2 5

Adcetris

Pfizer

Phase 2

1 6

Tecentriq

Roche

Phase 2

1 7

Afinitor

Novartis

Phase 2

1 8

Verzenio

Eli Lilly

Phase 2

1 9

Ellence

Merck & Co.

Phase 2

1 10

Iressa

AstraZeneca

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Recruiting

Malignant Mesothelioma

NCT06566079

Clinical

Trials by Indication[1]

Malignant Mesothelioma1 trial

Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors

Recruiting·IInSilico Medicine Hong Kong Limited·Phase 1·NCT06566079·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ISM6331. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ISM6331 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ISM6331. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — InSilico Medicine Hong Kong Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: IInSilico Medicine Hong Kong Limited

ISM6331

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Malignant Mesothelioma1 trial

References

Drug Info

Quick Facts

Related News